Catalyst Pharmaceuticals, Inc. (CPRX)
CPRX Stock Price Chart
Explore Catalyst Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CPRX price movements and trends.
CPRX Company Profile
Discover essential business fundamentals and corporate details for Catalyst Pharmaceuticals, Inc. (CPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2006
Employees
181.00
Website
https://www.catalystpharma.comCEO
Richard John Daly
Description
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
CPRX Financial Timeline
Browse a chronological timeline of Catalyst Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.48, while revenue estimate is $155.79m.
Earnings released on 11 May 2026
EPS came in at $0.52 falling short of the estimated $0.64 by -18.75%, while revenue for the quarter reached $149.34m , missing expectations by -0.12%.
Earnings released on 25 Feb 2026
EPS came in at $0.68 surpassing the estimated $0.42 by +61.90%, while revenue for the quarter reached $152.50m , beating expectations by +6.84%.
Earnings released on 5 Nov 2025
EPS came in at $0.68 surpassing the estimated $0.51 by +33.33%, while revenue for the quarter reached $148.39m , beating expectations by +3.95%.
Earnings released on 6 Aug 2025
EPS came in at $0.68 surpassing the estimated $0.58 by +17.24%, while revenue for the quarter reached $146.56m , beating expectations by +4.36%.
Earnings released on 7 May 2025
EPS came in at $0.68 surpassing the estimated $0.53 by +28.30%, while revenue for the quarter reached $141.42m , beating expectations by +7.85%.
Earnings released on 26 Feb 2025
EPS came in at $0.70 surpassing the estimated $0.32 by +118.75%, while revenue for the quarter reached $141.82m , beating expectations by +5.68%.
Earnings released on 6 Nov 2024
EPS came in at $0.57 surpassing the estimated $0.49 by +16.33%, while revenue for the quarter reached $128.70m , missing expectations by -4.05%.
Earnings released on 7 Aug 2024
EPS came in at $0.56 surpassing the estimated $0.42 by +33.33%, while revenue for the quarter reached $122.71m , beating expectations by +9.69%.
Earnings released on 8 May 2024
EPS came in at $0.38 surpassing the estimated $0.34 by +11.76%, while revenue for the quarter reached $98.51m , missing expectations by -12.01%.
Earnings released on 28 Feb 2024
EPS came in at $0.53 surpassing the estimated $0.48 by +10.42%, while revenue for the quarter reached $110.57m , meeting expectations.
Earnings released on 8 Nov 2023
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $102.69m , missing expectations by -2.90%.
Earnings released on 9 Aug 2023
EPS came in at $0.33 surpassing the estimated $0.25 by +32.00%, while revenue for the quarter reached $99.58m , beating expectations by +1.98%.
Earnings released on 10 May 2023
EPS came in at $0.26 falling short of the estimated $0.32 by -18.75%, while revenue for the quarter reached $85.37m , missing expectations by -7.94%.
Earnings released on 15 Mar 2023
EPS came in at $0.22 surpassing the estimated $0.21 by +4.76%, while revenue for the quarter reached $60.76m , beating expectations by +4.59%.
Earnings released on 9 Nov 2022
EPS came in at $0.20 surpassing the estimated $0.19 by +5.26%, while revenue for the quarter reached $57.24m , beating expectations by +6.61%.
Earnings released on 9 Aug 2022
EPS came in at $0.20 surpassing the estimated $0.17 by +17.65%, while revenue for the quarter reached $53.11m , beating expectations by +7.92%.
Earnings released on 10 May 2022
EPS came in at $0.12 falling short of the estimated $0.14 by -14.29%, while revenue for the quarter reached $43.09m , beating expectations by +0.78%.
Earnings released on 16 Mar 2022
EPS came in at $0.09 falling short of the estimated $0.12 by -25.00%, while revenue for the quarter reached $38.31m , beating expectations by +0.33%.
Earnings released on 9 Nov 2021
EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $35.95m , beating expectations by +3.94%.
Earnings released on 9 Aug 2021
EPS came in at $0.16 surpassing the estimated $0.09 by +77.78%, while revenue for the quarter reached $36.37m , beating expectations by +7.74%.
CPRX Stock Performance
Access detailed CPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
